Corcept Therapeutics Inc (CORT)
50.07
+2.45
(+5.14%)
USD |
NASDAQ |
Nov 04, 16:00
50.07
0.00 (0.00%)
After-Hours: 20:00
Corcept Therapeutics Revenue (Quarterly): 182.55M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 182.55M |
| June 30, 2024 | 163.80M |
| March 31, 2024 | 146.81M |
| December 31, 2023 | 135.40M |
| September 30, 2023 | 123.60M |
| June 30, 2023 | 117.72M |
| March 31, 2023 | 105.65M |
| December 31, 2022 | 103.06M |
| September 30, 2022 | 101.73M |
| June 30, 2022 | 103.39M |
| March 31, 2022 | 93.69M |
| December 31, 2021 | 98.82M |
| September 30, 2021 | 96.13M |
| June 30, 2021 | 91.59M |
| March 31, 2021 | 79.44M |
| December 31, 2020 | 85.74M |
| September 30, 2020 | 86.33M |
| June 30, 2020 | 88.56M |
| March 31, 2020 | 93.25M |
| December 31, 2019 | 87.90M |
| September 30, 2019 | 81.50M |
| June 30, 2019 | 72.26M |
| March 31, 2019 | 64.83M |
| December 31, 2018 | 66.83M |
| September 30, 2018 | 64.44M |
| Date | Value |
|---|---|
| June 30, 2018 | 62.31M |
| March 31, 2018 | 57.66M |
| December 31, 2017 | 53.28M |
| September 30, 2017 | 42.76M |
| June 30, 2017 | 35.56M |
| March 31, 2017 | 27.60M |
| December 31, 2016 | 23.81M |
| September 30, 2016 | 21.72M |
| June 30, 2016 | 19.72M |
| March 31, 2016 | 16.06M |
| December 31, 2015 | 14.97M |
| September 30, 2015 | 13.26M |
| June 30, 2015 | 11.96M |
| March 31, 2015 | 10.10M |
| December 31, 2014 | 9.014M |
| September 30, 2014 | 7.282M |
| June 30, 2014 | 5.851M |
| March 31, 2014 | 4.405M |
| December 31, 2013 | 4.115M |
| September 30, 2013 | 2.634M |
| June 30, 2013 | 1.891M |
| March 31, 2013 | 1.717M |
| December 31, 2012 | 1.377M |
| September 30, 2012 | 1.055M |
| June 30, 2012 | 0.875M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
79.44M
Minimum
Mar 2021
182.55M
Maximum
Sep 2024
109.26M
Average
100.28M
Median
Revenue (Quarterly) Benchmarks
| ADMA Biologics Inc | 107.19M |
| Akebia Therapeutics Inc | 43.65M |
| Bioventus Inc | 151.22M |
| Alnylam Pharmaceuticals Inc | 500.92M |
| Catalyst Pharmaceuticals Inc | 122.71M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 47.21M |
| Total Expenses (Quarterly) | 135.95M |
| EPS Diluted (Quarterly) | 0.41 |
| Enterprise Value | 4.609B |
| Gross Profit Margin (Quarterly) | 98.43% |
| Profit Margin (Quarterly) | 25.86% |
| Earnings Yield | 2.52% |
| Operating Earnings Yield | 2.57% |
| Normalized Earnings Yield | 2.516 |